-
摘要: 急性髓系白血病(acute myeloid leukemia,AML)是一种高度异质性的恶性血液病,近些年随着化疗、靶向药物和造血干细胞移植的发展,AML患者的疗效已有较大的提高,但总体而言,绝大部分患者仍无法治愈。目前,成人AML患者5年生存率仍未超过30%。嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)疗法在复发难治性B淋巴细胞肿瘤领域取得了显著疗效,越来越多的研究开始研发CAR-T疗法在其他类型肿瘤及疾病中的应用。本文主要就近些年CAR-T疗法在AML中的临床应用和研究进展做出综述。Abstract: Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy. In recent years, with the development of chemotherapy, targeted drugs, and hematopoietic stem cell transplantation, the efficacy of treatment for patients with AML has greatly improved; however, most patients remain incurable. The 5-year survival rate of adult patients with AML remains<30%. The efficacy of chimeric antigen receptor (CAR) T-cell therapy for relapsed and refractory B-lymphocyte tumors has been significant, and an increasing number of studies have begun developing the application of CAR T-cell therapy for other types of tumors and diseases. This study reviews the clinical application and research progress of CAR T- cell therapy for AML in recent years.
-
[1] 中华医学会血液学分会白血病淋巴瘤学组.中国复发难治性性性急性髓系白血病诊疗指南(2021年版)[J].中华血液学杂志,2021,42(8):624-627. doi: 10.3760/cma.j.issn.0253-2727.2021.08.002 [2] Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy[J]. Nat Rev Clinical Oncol, 2020, 17(3):147-167. doi: 10.1038/s41571-019-0297-y [3] Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies[J]. Blood Cancer J, 2021, 11(4):1-11. [4] Philipson BI, O’Connor RS, May MJ, et al. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling[J]. Sci Sign, 2020, 13(625):eaay8248. doi: 10.1126/scisignal.aay8248 [5] Wang Q, Wang Y, Lv H, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia[J]. Molecular therapy, 2015, 23(1):184-191. [6] Tambaro FP, Singh H, Jones E, et al. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia[J]. Leukemia, 2021, 35(11):3282-3286. doi: 10.1038/s41375-021-01232-2 [7] Liu Y, Wang S, Schubert ML, et al. CD33‐directed immunotherapy with third‐generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33‐edited acute myeloid leukemia and hematopoietic stem and progenitor cells[J]. Int J Cancer, 2021, 42(2):234-236. [8] Jones LM, Tarlock K, Cooper T. Targeted therapy in pediatric AML: an evolving landscape[J]. Paediatr Drugs, 2021, 23(5):485-497. doi: 10.1007/s40272-021-00467-x [9] Sun Y, Chen JL, Liu YR, et al. Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML[J]. Front Oncol, 2019, 9:1358. doi: 10.3389/fonc.2019.01358 [10] Riberdy JM, Zhou S, Zheng F, et al. The art and science of selecting a CD123-specific chimeric antigen receptor for clinical testing[J]. Mol Ther Methods Clin Dev, 2020, 18:571-581. doi: 10.1016/j.omtm.2020.06.024 [11] Ataca Atilla P, McKenna MK, Tashiro H, et al. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR-T cells to safely eliminate acute myeloid leukemia[J]. J Immunother Cancer, 2020, 8(2):e001229. doi: 10.1136/jitc-2020-001229 [12] Fiorenza S, Turtle CJ. CAR-T cell therapy for acute myeloid leukemia: preclinical rationale, current clinical progress, and barriers to success[J]. Bio Drugs, 2021, 35(3):281-302. [13] Qu CJ, Li Z, Kang LQ, et al. Successful treatment of two relapsed/refractory t(8;21)acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells[J]. Bone Marrow Transplant, 2019, 54(7):1138-1140. doi: 10.1038/s41409-018-0423-y [14] Danylesko I, Jacoby E, Yerushalmi R, et al. Remission of acute myeloid leukemia with t(8;21)following CD19 CAR T-cells[J]. Leukemia, 2020, 34(7):1939-1942. doi: 10.1038/s41375-020-0719-y [15] Marofi F, Rahman HS, Al-Obaidi ZMJ, et al. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients[J]. Stem Cell Res Ther, 2021, 12(1):465. doi: 10.1186/s13287-021-02420-8 [16] Sallman DA, Brayer JB, Poire X, et al. Results from the completed dose-escalation of the hematological arm of the phase I think study evaluating multiple infusions of NKG2D-based CAR T-cells As standalone therapy in relapse/refractory acute myeloid leukemia and myelodysplastic syndrome patients[J]. Blood, 2019, 134(Supple_1):3826. [17] Marvin-Peek J, Savani BN, Olalekan OO, et al. Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia[J]. Cancers (Basel), 2022, 14(3):497. doi: 10.3390/cancers14030497 [18] Cui QY, Qian CS, Xu N, et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation[J]. J Hematol Oncol, 2021, 14(1):82. doi: 10.1186/s13045-021-01092-4 [19] Wang Y, Xu YX, Li SS, et al. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells[J]. J Hematol Oncol, 2018, 11(1):60. doi: 10.1186/s13045-018-0603-7 [20] Shrestha E, Liang R, Sirochinsky C, et al. Preclinical development of anti-FLT3 CAR-T therapy for the treatment of acute myeloid leukemia[J]. Blood, 2020, 136:4-5. [21] Ghamari A, Pakzad P, Majd A, et al. Design and production an effective bispecific tandem chimeric antigen receptor on T cells against CD123 and folate receptor ß towards B-acute myeloid leukaemia blasts[J]. Cell J, 2021, 23(6):650-657. [22] Michelozzi IM, Kirtsios E, Giustacchini A. Driving CAR T stem cell targeting in acute myeloid leukemia: the roads to success[J]. Cancers, 2021, 13(11):2816. doi: 10.3390/cancers13112816 [23] Hazelton W, Ghorashian S, Pule M. Nanobody based tri-specific chimeric antigen receptor to treat acute myeloid leukaemia[J]. Blood, 2020, 136:10-11. [24] Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies[J]. J Allergy Clin Immunol, 2020, 146(5):940-948. doi: 10.1016/j.jaci.2020.07.025 [25] Wallet F, Sesques P, Devic P, et al. CAR-T cell: Toxicities issues: mechanisms and clinical management[J]. Bull Cancer, 2021, 108(10S):S117-S127.
点击查看大图
计量
- 文章访问数: 662
- HTML全文浏览量: 129
- PDF下载量: 228
- 被引次数: 0